Bile and Bile Duct/Pancreatic Duct Brushings Database for Patients With Pancreato-biliary Stricture
The purpose of this study is to create a long-term storage of bile and brushings of pancreato-biliary duct in patients diagnosed with pancreato-biliary stricture for future research.
Recently, a lot of research has been done to test for certain markers in the bile and brushings to detect cancer in a stricture. The samples will be used to measure biomarkers (proteins) in biliary diseases.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Bile and Bile Duct/Pancreatic Duct Brushings Database for Patients With Pancreato-biliary Stricture|
Bile and bile duct/pancreatic duct brushings
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||February 2015 (Final data collection date for primary outcome measure)|
Patients with pancreatic/biliary strictures
Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
Other: sample collection
bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
Recently, a lot of research has been done to test for certain markers like fluorescence in situ hybridization (FISH), digital image analysis (DIA), and quantifiable morphometric results in biliary stricture brushings. Recently, polysomy FISH has been studied as a promising marker in predicting cancer in a pancreato-biliary stricture. Many genetic, epigenetic, and protein alterations arise during pancreaticobiliary tumor process. The types of markers that have been commonly evaluated as diagnostic assays are mutations, chromosomal gains and losses, and DNA methylation alterations. However there are only a few studies in this area. Testing for these markers can help determine whether the narrowing or stricture in your bile duct is cancer or not.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01565460
|Contact: Udayakumar Navaneethan, MDemail@example.com|
|Contact: Mansour Parsi, MDfirstname.lastname@example.org|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Contact: Udayakumar Navaneethan, MD 216-636-9230 email@example.com|
|Contact: Susan Thomas, RN 216-444-5930 firstname.lastname@example.org|
|Principal Investigator: Udayakumar Navaneethan, MD|
|Principal Investigator:||Udayakumar Navaneethan, MD||The Cleveland Clinic|